Overall, our findings suggest that targeting the Akt/mTOR signaling pathway may deserve exploration as a potential therapeutic strategy for CRC treatment and imply that Ziyu-II might serve as a promising agent for autophagy stimulators. This evidence concerns the gene AKT1 and colorectal carcinoma.